Unlike monoclonal antibody and receptor fusion protein therapy approaches, gene therapies for AMD target native ocular tissue to deliver a one-time genetic payload capable of sustained anti-VEGF protein production [33]. The gene discussed is VEGFA; the disease is age-related macular degeneration.